Tamoxifen has been a mainstay of breast cancer treatment for decades, but a new study suggests the eye monitoring that should accompany it is rarely happening. Researchers found that only about 7 percent of patients received recommended ophthalmic follow-up within a year of starting the drug.
Inside the Numbers
The analysis drew on the National Institutes of Health’s All of Us Research Program, examining records for 5,136 participants, including 2,327 tamoxifen users and 2,809 users of aromatase inhibitors for comparison. Just 7.0 percent of tamoxifen patients had an ophthalmic encounter within a year of beginning treatment, and only 1.7 percent underwent retinal imaging such as OCT scans or fundus photography. Patients who already had glaucoma or diabetic retinopathy fared better, at a 25 percent encounter rate, compared with 6.3 percent for those without pre-existing eye conditions.
Why Tamoxifen Monitoring Matters
Tamoxifen is associated with retinal toxicity, a side effect that can threaten vision if it goes undetected. The researchers argue that the low monitoring rates expose a systems problem: in the United States there are currently no formal screening guidelines mandating eye checks for tamoxifen patients, so follow-up depends on individual clinicians remembering to arrange it. Readers who follow more medical research coverage will have seen similar care-gap findings across other long-term medications.
What the Study Can and Cannot Say
As the full report on the monitoring gap reports, the investigators adjusted their analysis for demographics and pre-existing conditions, but observational data of this kind identifies patterns rather than proving why they occur. The authors’ hope is that quantifying the gap strengthens the case for formal screening guidance, so that eye surveillance becomes a standard part of tamoxifen care rather than an afterthought.
For a drug taken by large numbers of patients over many years, even a small percentage gap represents a great many unmonitored eyes. This study gives policymakers a number to act on.
